Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20
- 8 May 2009
- journal article
- research article
- Published by Elsevier BV in Molecular Immunology
- Vol. 46 (11-12), 2419-2423
- https://doi.org/10.1016/j.molimm.2009.04.009
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood, 2008
- Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma EffectsHematology-American Society Hematology Education Program, 2007
- The epitope recognized by rituximabBlood, 2006
- Antibody Elbow Angles are Influenced by their Light Chain ClassJournal of Molecular Biology, 2006
- Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursorBlood, 2006
- Mouse opens door for study of autoimmune diseasesNature, 2004
- Standard conformations for the canonical structures of immunoglobulins 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1997
- Comparison of CH1 Domains in Different Classes of Murine AntibodiesJournal of Molecular Biology, 1996
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.The Journal of cell biology, 1993